News - Page 7 of 11 - Vaccibody.com
8
blog,paged,paged-7,bridge-core-2.4.3,qode-page-transition-enabled,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-25.7,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,wpb-js-composer js-comp-ver-6.6.0,vc_responsive

April 4, 2018

Posted at 12:00h in Uncategorized

Vaccibody AS, a clinical stage immunotherapy company focused on developing personalized neoantigen cancer vaccines to target solid tumors, today announces informed consent signed by the first patient and enrolment process initiated in the clinical trial. The patient will be enrolled in Heidelberg, Germany at the...

April 3, 2018

Posted at 08:28h in Uncategorized

Vaccibody calls for Annual General Meeting to be held on April 10, 2018 at 10.00 AM in Forskningsparken, Oslo. Shareholders will receive the call documents electronically or by post. The call documents can also be downloaded here....

March 8, 2018

Posted at 12:05h in Uncategorized

Vaccibody AS, a clinical stage company focused on developing personalized neoepitope cancer vaccines to target solid tumors, today announces approval of Clinical Trial Application (CTA) for its cancer neoantigen phase I/IIa trial by German regulatory authorities (Paul Ehrlich Institute (PEI)). Dr. Martin Bonde, Chief Executive Officer...

March 1, 2018

Posted at 09:45h in Uncategorized

Vaccibody AS, a clinical stage company focused on developing personalized neoepitope cancer vaccines to target solid tumors, will host a capital markets day and invites analysts, brokers, investors and press to presentations by the members of the company’s executive management team and by Principal Investigator...

January 24, 2018

Posted at 10:00h in Uncategorized

Vaccibody AS, a clinical stage company focused on developing personalized neoepitope cancer vaccines to target solid tumors, today announces conditional approval of Clinical Trial Application (CTA) for its cancer neoantigen phase I/IIa trial by German regulatory authorities (Paul Ehrlich Institute (PEI)). The Company estimates that...

January 8, 2018

Posted at 10:00h in Uncategorized

Vaccibody AS, a clinical stage company focused on developing personalized neoepitope cancer vaccines to target solid tumors, today announces pre-clinical data supporting elicitation of strong killer T cell responses (CD8+ T cells) towards cancer neoantigens. The executive management is present at JP Morgan in San...

December 12, 2017

Posted at 10:00h in Uncategorized

  Finalization of enrolment in the HPV16 therapeutic vaccine (VB10.16) phase IIa of trial VB C-01. Vaccibody AS announces that enrolment of patients will be finalised in December 2017 for the expansion phase (phase IIa) of its multicentre trial VB C-01. The enrolment goal was 15-20 patients...

August 3, 2017

Posted at 11:00h in Uncategorized

Clinical Trial Application for VB10.NEO filed with PEI Vaccibody AS today announced filing of a Clinical Trial Application (CTA) for cancer neoantigen vaccine VB10.NEO with German regulatory authority Paul Ehrlich Institute (PEI). VB10.NEO is a personalized vaccine designed specifically for each patient and the neoantigen mutations...